Trial Profile
RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RESILIENT
- Sponsors Ipsen; Merrimack Pharmaceuticals
- 11 Aug 2023 This Trial has been completed in Hungary as per European Clinical Trials Database record.
- 08 Aug 2023 Status changed from active, no longer recruiting to completed.
- 13 Jul 2023 Planned End Date changed from 28 Apr 2023 to 31 Jul 2023.